Your browser doesn't support javascript.
Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.
Altieri, Manuela; Capuano, Rocco; Conte, Miriana; Donnarumma, Giovanna; Grimaldi, Elena; Coppola, Nicola; Galdiero, Massimiliano; d'Ambrosio, Alessandro; Tedeschi, Gioacchino; Gallo, Antonio.
  • Altieri M; Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Capuano R; Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Conte M; Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Donnarumma G; Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Grimaldi E; Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Coppola N; Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Galdiero M; Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • d'Ambrosio A; Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Tedeschi G; Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Gallo A; Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy. antonio.gallo@unicampania.it.
Neurol Sci ; 43(5): 2947-2949, 2022 May.
Article in English | MEDLINE | ID: covidwho-1694524
ABSTRACT

BACKGROUND:

Few studies investigated the immune response to SARS-CoV-2 vaccine in patients with multiple sclerosis (pwMS) treated with natalizumab (NTZ) and found a short-term efficient humoral response; however, there are no studies assessing the levels of SARS-CoV-2 IgG antibodies in pwMS treated with NTZ over time.

METHODS:

Humoral immune response to BNT162b2 mRNA COVID-19 vaccine was assessed in a group of 26 pwMS on NTZ up to 6 months after a full COVID-19 vaccination cycle and compared it with 43 age- and sex-matched group of HC. Serum samples were collected before the first dose (T0), and 4 weeks (T1) and 6 months (T2) after the first dose of BNT162b2 mRNA COVID-19 vaccine. The LIAISON® SARS-CoV-2 TrimericS-IgG assay (DiaSorin-S.p.A.) was employed for the detection of IgG antibodies to SARS-CoV-2 spike protein (cutoff for positive IgG antibodies 33.8 BAU/mL).

RESULTS:

At T1 and T2, both groups showed an efficient humoral response to BNT162b2 mRNA COVID-19 vaccine. A significant reduction of IgG antibodies to SARS-CoV-2 spike protein was detected at T2 both in pwMS and in HC, but SARS-CoV-2 IgG antibodies were still above the cutoff limit in all participants.

CONCLUSIONS:

pwMS on NTZ develop and maintain a long-term humoral response after a full COVID-19 vaccination cycle comparable to their healthy peers, and these findings are relevant for clinicians called to counsel about COVID-19 mRNA vaccine timing and booster doses in pwMS treated with NTZ.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Neurol Sci Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: S10072-022-05940-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Neurol Sci Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: S10072-022-05940-0